Cardiovascular disease research and diagnosis in cancer patients are being redefined by new technology: a technology that promises computational methodology to reduce human error, increase personalized medicine, and streamline treatments to drive unprecedented results in cancer patients. CardioCan is pushing its technology past the limits of traditional lab methodologies in diagnosing cardiovascular diseases in cancer patients with its digital platform and pipeline of AI applications. Developed by a combination of medical advisors and software developers, CardioCan is transforming the economics and practice of oncology, putting the power of early diagnosis and treatment of cardiovascular diseases using data-centric algorithms to work in the fight against cancer.